Evolution of capecitabine dosing in colorectal cancer

Clinical Colorectal Cancer

Volumn 9, Issue 1, 2010, Pages 31-39

  Sun, Weijing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 Fluorouracil; MFOLFOX6; Neuropathy; Renal impairment; XELIRI; XELOX

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; COUMARIN ANTICOAGULANT; CYTOCHROME P450 2C9; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PHENPROCOUMON; WARFARIN;

ABDOMINAL PAIN; AGE; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COMORBIDITY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE CALCULATION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; HAND FOOT AND MOUTH DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INDIVIDUALIZATION; KIDNEY FUNCTION; LEUKOPENIA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC ACTIVATION; METASTASIS; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PARESTHESIA; RADIOSENSITIZATION; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77149134017     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.004     Document Type: Review

References (33)

1. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16:1795-1802
2. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16:2977-2985
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. V.2.2009. Available at: http://www.nccn.org/ professionals/ physician-gls/PDF/colon.pdf. Accessed March 2, 2009.
4. Budman DR, Lichtman SM. Investigational drugs. In: Perry MC, ed. The Chemotherapy Sourcebook. 2nd ed. Baltimore, MD: Williams & Wilkins; 1996:479-558.
5. Xeloda (capecitabine) prescribing information. Nutley, NJ: Roche Laboratories Inc. Revised April 2006. Available at: http://www.rocheusa.com/ products/xeloda/. Accessed: March 2, 2009.
6. Cassidy J, Dirix L, Bissett D, et al. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998; 4:2755-2761
7. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292
8. Van Cutsem E, Twelves C, Cassidy J, et al; Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106
9. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352:2696-2704
10. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006-2012
11. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19:1720-1726
12. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26:2118-2123
13. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47:2203-2206
14. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18:1337-1345
15. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:2084-2091
16. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947
17. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study [erratum in: J Clin Oncol 2008; 26:4697]. J Clin Oncol 2008; 26:3523-3529
18. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25:102-109
19. Sharma R, Rivory L, Beale P, et al. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006; 94:964-968
20. Reinacher-Schick AC, Kubicka S, Freier W, et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol 2008 26(suppl):185s (abstract 4030).
21. Kohne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19:920-926
22. De Paoli A, Chiara S, Luppi G, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006; 17:246-251 (Pubitemid 43160113)
23. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66:762-771
24. Cassidy J, Twelves C, Van Cutsem E, et al Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566-575
25. Scheithauer W, McKendrick J, Begbie S. X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14:1735-1743
26. Macintosh PW, Pond GR, Pond BJ, Leung V, Siu LL. A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl) 2007; 16:380-386
27. Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004; 8(suppl 1):S41-53.
28. Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer 2006; 6:278-287
29. Cassidy J. Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. Clin Colorectal Cancer 2005; 5(suppl 1):S47-50.
30. Rothenberg ML, Saltz L, Cunningham D, et al. Tolerability of fluoropyrimidines in combination with oxaliplatin appears to differ by region. American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 456.
31. Midgley R, Kerr DJ. Capecitabine: Have we got the dose right? Nat Clin Pract Oncol 2009; 6:17-24.
32. Ho C, Vincent M, Jonker D, et al. Folate, SAH, and SAM levels and the risk of severe toxicity in colorectal cancer patients treated with 5-FU and folinic acid. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract 216.
33. Haller D, Tabernero J, Maroun F, et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Eur J Cancer 2009; 7(suppl):4 (abstract 5LBA).